Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 6;18(1):69.
doi: 10.1186/s13223-022-00707-w.

Drug-induced hypersensitivity syndrome induced by propylthiouracil: case report and literature review

Affiliations

Drug-induced hypersensitivity syndrome induced by propylthiouracil: case report and literature review

Fang Wu et al. Allergy Asthma Clin Immunol. .

Abstract

Background: Drug-induced hypersensitivity syndrome (DIHS) is a rare, potentially life-threatening systemic drug reaction. Antithyroid drugs (ATDs) causing DIHS have seldom been reported before.

Case presentation: We present a case of propylthiouracil (PTU)-induced DIHS, which included fever, skin rash, lymphadenopathy, hepatosplenomegaly, serious liver and kidney dysfunction, peripheral blood eosinophilia, and atypical lymphocytosis. Following supportive therapy, intravenous immunoglobulin (IVIG), and systemic corticosteroid, the patient experienced a resolution of fever and rash combined with progressive normalization of hematological index and organ function. These clinical features, and the skin lesion biopsy confirmed DIHS diagnosis.

Conclusions: To our knowledge, this is the second reported case of PTU-induced DIHS worldwide and the first human leukocyte antigen (HLA) typing of PTU-induced DIHS. Clinicians should cautiously distinguish hyperthyroidism etiology and identify the indication of ATDs. Timely recognition and formal DIHS treatment are required in patients with ATDs.

Keywords: Drug-induced hypersensitivity syndrome; Human leukocyte antigen; Propylthiouracil.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Haematoxylin and eosin staining of the skin biopsy. Finding from the skin biopsy: dermal lymphocytic infiltrate and occasional perivascular monocytic infiltrate, with the presence of interface vacuolization (a), perifollicular lymphocytic infiltration (b), epidermal spongiosis (c). Hematoxylin and eosin stain; original magnification: X200

Similar articles

Cited by

References

    1. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083–1084. doi: 10.1111/j.1365-2133.2007.07807.x. - DOI - PubMed
    1. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2006;155:422–428. doi: 10.1111/j.1365-2133.2006.07284.x. - DOI - PubMed
    1. Botelho LF, Higashi VS, Padilha MH, Enokihara MM, Porro AM. DRESS: clinicopathological features of 10 cases from an University Hospital in Sao Paulo. An Bras Dermatol. 2012;87:703–707. doi: 10.1590/S0365-05962012000500005. - DOI - PubMed
    1. Jeung YJ, Lee JY, Oh MJ, Choi DC, Lee BJ. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res. 2010;2:123–126. doi: 10.4168/aair.2010.2.2.123. - DOI - PMC - PubMed
    1. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–1080. doi: 10.1111/bjd.12501. - DOI - PubMed